COVID-19: Computational screening of our entire molecule library

In the process of developing new medicines, our scientists have built a vast library of more than one million compounds over time. In our quest to support the fight against COVID-19 with all scientific capabilities at Boehringer Ingelheim, we are conducting a computational screen of our entire library. With this, we aim to identify novel small molecules with activity against the virus.